Introduction
Section 01

"Man communicates via the written word.”
Nature abhors a vacuum: with the same intensity it abhors new ideas.
(CRS)

No Federal or Public Funds have been used in any aspect of the initial studies, manuscript preparation or final formulation of this theory or in support of this website: www.Liver-Brain-Theory.com/

Parkinson’s disease, the oldest known degenerative brain disease, affects one million Americans, initially described in 1817, is the second most common degenerative brain disease, afflicting one million Americans. Its current name was suggested by Jean Martin Charcot in recognition of Parkinson’s initial description of the “shaking palsy” he observed in several of his patients.

Clinical manifestations are characterized by muscle stiffness, shaking, difficulty walking in addition to abnormal thinking and a variety of emotional problems including dementia and psychotic behavior in the later stages of this disease. Substantial progress has made in understanding its basic pathology as it is now known to begin in a specific part of the brain, the Substantia Nigra, resulting is deficient production of dopamine, a vital neurotransmitter. The proximate cause is still unknown more than two centuries after it was recognized to be a unique degenerative brain disease.

It appears that the wide variety and the severity of its clinical manifestations is duration dependent as a consequence of progressive destruction of dopamine producing cells ultimately leading to severely physically impaired patients approximately a decade after its initial recognition. A major advance in clinical treatment resulted from the initial synthesis of a variety of dopamine compounds in the 1970’s. Even the most senior experienced neurologists are frequently baffleled in selecting optimum treatment regimens on a day to day basis for the multitude of Parkinson’s patients seen in major clinics throughout America.

It is the author’s opinion that the “Parkinson’s Foundations” provide the most helpful advice and support to patients, families and treating physicians than any of the associated namesake organizations while the ALS organization appears to be the least helpful of all.

Amyotrophic Lateral Sclerosis (ALS), a.k.a. Lou Gehrig’s disease, or “motor neuron disease” as it is named in most Europe countries was initially described in a single patient in 1824 in London, England but definitively recognized as a distinct entity in 1867 by the Father of Neurology, French Neurologist, Jean-Martin Charcot.

 

ALS was rarely diagnosed or recognized in America until 1939 when it afflicted Lou Gehrig then one of the best recognized baseball players in the world. Gehrig died 25 months to the day he took himself out of the Yankee starting lineup “for the good of the team” at age 37. Death occurs in 80-90% of afflicted patients in less than 4-5 years resulting from progressive muscle weakness that deprives afflicted patients of their ability to breathe and swallow. The prognosis is so dismal in ALS afflicted patients that suicide is 6 times more common in many Scandinavian countries than any other disease.

 

ALS lends itself to more detailed study than any of the other degenerative brain diseases in that the rate of progressive loss of muscle strength can be measured repetitively with decimal like accuracy over time using inexpensive measuring devices.

Multiple Sclerosis was also recognized as distinct entity by Jean-Martin-Charcot in 1868. Multiple Sclerosis is a chronic, usually progressive disease involving damage to the sheaths of nerve cells in the brain and spinal cord. It too appears to be a disease of aging becoming most common after 65. It is unusual in that clinical manifestations are quite variable from one patient to another. Symptoms may include episodic numbness, speech impairment, muscular incoordination, blurred vision, and intermittent, inexplicable fatigue. Current thinking is that there is an auto-immune component of variable intensity in most of the estimated two and a half million afflicted patients in the world

Dr. Alois Alzheimer presented the clinical details of Auguste “D” Deter’s progressive loss of her memory at a local medical meeting in Bavaria, Germany in 1906-7. Colleague’s subsequently referred to similar patients as having Alzheimer’s disease.

Auguste “D” developed dramatic and progressive memory loss with associated erratic and psychotic behavior beginning in her forties. Dr. Alzheimer and August “D” Deter met by serendipity in the local insane asylum where Dr. Alzheimer took his first position after being trained as a psychiatrist and neuropathologist. Dr. Alzheimer was so fascinated by her erratic and intermittent psychotic behavior and ever changing answers to similar questions that he personally recorded in his own handwriting specific clinical details of her progressive brain dysfunction.

When Dr. Alzheimer’s notes were found shortly after the centennial anniversary of his original description of Auguste “D” illness, they required the help of Linguistic scholars to be interpretable.

Dr. Alzheimer was able to examine her brain following her death April 6, 1906. As silver stains had recently become available he recognized and described the nerve tangles now diagnostic of his namesake disease.

Alzheimer’s exists in an estimated 35-45 million patients in the world today including 5.2–5.4 million Americans. It is characteristically a disease of aging in that more than 90-95% of patients are diagnosed after age 65. Typical of all degenerative brain diseases is that the incidence increases as a function of age. It is nearly twice as common in Caucasian females as males but the sex ratio is relatively equal in blacks and Hispanics in America. On the other hand the age specific incidence is greater in blacks and Hispanics than Caucasians.

It continues to be the single most common and expensive degenerative brain disease to treat in view of the fact that nearly 100% of afflicted patients require terminal domiciliary nursing care for several years prior to their death. The Japanese Government has estimated that the cost of caring for their patients with Alzheimer’s approximates 1% of their gross national product. (5 trillion US $ +/-)

Additionally, there are several million Americans with “Non Vascular forms of Senile Dementia”, (hereafter to be named: “Primary Dementia”) all without known cause or cure. Clinical manifestations are characterized by variable, but progressive loss of social skills and memory. A relatively high percent of patients with Primary Dementia insidiously progress to develop Alzheimer’s disease over a period of 5-10 years or longer: (the prodromal periods of Alzheimer’s). The variety of clinical findings present in patients with Primary Dementia is sufficiently variable and amorphous to preclude meaningful classification, enumeration or study.

The author chooses to group “Age Related Macular Degeneration” as a distinct variant of degenerative brain diseases as the macular of the eye is composed of specialized extra cranial brain cells with the unique ability to recognize light, colors which are transmitted to the intracranial brain and stored in memory cells with extraordinary precision over decades: “photographic memory’. It is non-fatal disease, usually of unknown cause, that may well afflict 1% of senior citizens possibly leading to blindness. Recommended treatment programs aim to improve the nutrition to the macular. Treatment regimens appear to be beneficial but vision loss has yet to be reversed.

The "Liver-Brain-Theory” is the single most comprehensive and testable theory ever developed. It is now published attempting to explain the origin(s) and progressive clinical course of any or all types of degenerative brain diseases currently known to exist.

The author openly predicts that many of these heretical ideas will prove relevant, if not prescient. Currently it is virtually impossible to find a reputable medical journal willing to publish any new ideas or theories relevant to neurodegenerative diseases: even a simple theory as short as 134 words in length was rejected by two prominent medical journals as recently as September, 2014. Even the ALS organization refused to publish or cite these heretical ideas pertinent to ALS, their primary reason to exist.

This web site will encourage and welcome other investigators an opportunity to publish their own ideas concerning any other possible causes of neurodegenerative diseases. Additionally this site will provide a public forum for other thoughtful and knowledgeable individuals to exchange ideas without concern of being ridiculed. Should we be able to reason together, more cogent and relevant theories pertinent to these debilitating diseases will most likely be developed within a year or two.

Despite the fact that physicians have been aware of ALS, an inevitably fatal disease, for nearly two hundred years, Alzheimer’s for 110 years, and Parkinson’s for 200 years (more than 5 centuries in Toto), no one including the: NIH, the National Institute of Nervous and Mental Diseases, the Alzheimer's or ALS Association, any reputable Medical Journal or any Neurology Group, Society or Organization has had the courage or knowledge to publish a testable theory accounting for the Inciting Cause(s) and Progressive Nature of Any or All Degenerative Brain diseases cited above.

3/18/2018

←  Return to Preface Continue to Next Section  →